Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) Equity Average (2020 - 2025)

Historic Equity Average for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to $22.6 million.

  • Journey Medical's Equity Average rose 10315.92% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.6 million, marking a year-over-year increase of 10315.92%. This contributed to the annual value of $20.2 million for FY2024, which is 826.9% up from last year.
  • Per Journey Medical's latest filing, its Equity Average stood at $22.6 million for Q3 2025, which was up 10315.92% from $20.4 million recorded in Q2 2025.
  • Journey Medical's 5-year Equity Average high stood at $41.7 million for Q1 2022, and its period low was $3.7 million during Q2 2023.
  • In the last 5 years, Journey Medical's Equity Average had a median value of $17.8 million in 2023 and averaged $19.4 million.
  • In the last 5 years, Journey Medical's Equity Average plummeted by 9016.57% in 2023 and then skyrocketed by 22340.94% in 2024.
  • Over the past 5 years, Journey Medical's Equity Average (Quarter) stood at $15.2 million in 2021, then skyrocketed by 42.3% to $21.6 million in 2022, then dropped by 12.61% to $18.9 million in 2023, then dropped by 17.84% to $15.5 million in 2024, then surged by 45.65% to $22.6 million in 2025.
  • Its Equity Average was $22.6 million in Q3 2025, compared to $20.4 million in Q2 2025 and $20.8 million in Q1 2025.